14 completed, 8 recruiting, 7 active not recruiting, 4 terminated. 17 Phase 2, 16 Phase 3, 4 Phase 1, 1 Not applicable.
Follow azathiopurine: new trials by email Literature Review of azathiopurine trials Research Report on azathiopurine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | SWOG Cancer Research Network | 90 | 2026-10-14 | 2026-10-13 |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 53 | 2025-10-10 | 2026-10-13 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home Biospecimen Collection, Compliance Monitoring, Health Promotion and Education - Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia | Not applicable | Suspended | Children's Oncology Group | 64 | 2024-12-04 | 2026-10-05 |
| Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-09 | 2024-05-17 | |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride - B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 24 | 2022-03-17 | 2026-05-28 |
| Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Cyclophosphamide, Cytarabine, Dexamethasone - Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2022-02-17 | 2025-08-11 |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection - Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 461 | 2020-12-17 | 2026-09-01 |
| Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Cyclophosphamide, Cytarabine, Dexamethasone - Blastic Plasmacytoid Dendritic Cell Neoplasm | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2020-05-29 | 2026-09-14 |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Recruiting | Children's Oncology Group | 5951 | 2019-10-31 | 2026-08-25 |
| A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 6720 | 2019-07-03 | 2026-10-01 |
| Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2018-04-18 | 2022-11-04 |
| Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dexamethasone - Acute Lymphoblastic Leukemia in Remission, B Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2018-03-28 | 2026-07-30 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Azacitidine, Biospecimen Collection, Computed Tomography - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2017-04-01 | 2025-02-27 |
| Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2016-11-01 | 2026-05-20 |
| Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Cyclophosphamide, Cytarabine, Dasatinib - Recurrent B Acute Lymphoblastic Leukemia, Recurrent Ph-Like Acute Lymphoblastic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 11 | 2015-07-15 | 2025-06-08 |
| Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Biopsy Procedure, Biospecimen Collection, Blinatumomab - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 53 | 2015-06-30 | 2026-08-04 |
Showing 20 of 37. Sign in to see all of them.
Burkitt Lymphoma (22) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (7) · Leukemia, Biphenotypic, Acute (6) · Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (4) · Down Syndrome (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Carcinoma, Renal Cell (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Myofibroma (1)
National Cancer Institute (NCI) (14) · Children's Oncology Group (12) · M.D. Anderson Cancer Center (7) · City of Hope Medical Center (2) · Jonsson Comprehensive Cancer Center (1) · SWOG Cancer Research Network (1)
United States (35) · Canada (19) · Australia (17) · Puerto Rico (14) · New Zealand (12) · Switzerland (6) · Ireland (2) · Israel (2) · Austria (1) · Belgium (1) · Chile (1) · Czechia (1) · Finland (1) · France (1) · Germany (1)
Elias Jabbour (3) · Smita Bhatia (3) · Anne L Angiolillo (2) · Ibrahim Aldoss (2) · Andrea Biondi (1) · Anjali S Advani (1) · Brian Shuch (1) · David T Teachey (1) · Eric C Larsen (1) · Erin H Breese (1) · Farhad Ravandi-Kashani (1) · Ibrahim T Aldoss (1) · Jennifer L McNeer (1) · Joanne M Hilden (1) · John J Gregory (1)
PMID 37890117, PMID 39121442, PMID 41671463, PMID 26590194, PMID 29284596, PMID 35622074, PMID 36603187, PMID 38446568, PMID 40315406, PMID 42085640, PMID 23678006, PMID 24829202, PMID 24970932, PMID 25624441, PMID 26124497, PMID 26265699, PMID 29812996, PMID 30138085, PMID 30626253, PMID 32414848, PMID 32496902, PMID 32552472, PMID 32589970, PMID 32813610, PMID 32852553, PMID 33191168, PMID 33242441, PMID 33411585, PMID 33496745, PMID 33651090, PMID 33844429, PMID 34302711, PMID 34492682, PMID 35271306, PMID 36279879, PMID 36322825, PMID 37070673, PMID 37257143, PMID 37556734, PMID 38457359, PMID 38867582, PMID 39047240, PMID 39651791, PMID 40533067, PMID 40568722, PMID 40908865, PMID 41592282, PMID 42832396
U10CA180886 (14), U10CA098543 (12), P30CA016672 (3), U10CA180888 (3), P30CA033572 (2), U10CA095861 (2), UG1CA189955 (2), 2017 (1), R01CA096670 (1), R01CA174683 (1), U10CA021115 (1), U10CA031946 (1), U10CA098413 (1), U10CA180820 (1), U10CA180821 (1)